| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Arbutus Biopharma Corp
13D/A
ABUS · 03879J100
|
19.5% |
10/5/2026
Event 10/1/2026
|
||||
|
Immunovant, Inc.
13D/A
IMVT · 45258J102
|
55.9% |
12/12/2025
Event 12/12/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.